2024-03-28 17:01:46 ET
More on Applied Therapeutics
- Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
- Applied Therapeutics: Update Following Failure In Diabetic Cardiomyopathy (Downgrade)
- ARISE-HF Phase 3 Trial Likely To Disappoint Due To Multiple Red Flags
- Applied Therapeutics GAAP EPS of -$1.42 beats by $0.02, revenue of $10M misses by $0.67M
- Applied Therapeutics hits 52-week high on trial success
Read the full article on Seeking Alpha
For further details see:
Applied Therapeutics gets extension of FDA review for rare disease drug